Receiving any other investigational agent which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXReceiving any other investigational agent that would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXReceiving any other investigational agentXx_NEWLINE_xXReceiving any other investigational agentXx_NEWLINE_xXReceiving any other investigational agent that would be considered a treatment for the primary neoplasmXx_NEWLINE_xXThe participant has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXPrior investigational immunotherapyXx_NEWLINE_xXUse of an investigational agent within the past 30 daysXx_NEWLINE_xXTREATMENT: Patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent (everolimus or trametinib) or combination (AZD1775/combination or veliparib/temozolomide); instead, patients will receive an investigational agent or combination prospectively identified to work on a different target in their tumor�s mutation/aberrant pathwayXx_NEWLINE_xXSubjects must have received their last dose of investigational or biologic agent >= 7 days prior to study registration* In the event that a subject has received an investigational or biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to registration* If the investigational or biologic agent has a prolonged half-life (>= 7 days) then at least three (3) weeks must have elapsed prior to registrationXx_NEWLINE_xXPatients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)Xx_NEWLINE_xXBiologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is requiredXx_NEWLINE_xXPatients must NOT receive concurrent anti-cancer therapy or investigational agent unless specified in protocolXx_NEWLINE_xXPatients who are receiving any other investigational agent(s)Xx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXPatients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentXx_NEWLINE_xXThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentXx_NEWLINE_xXPatients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of 4 weeks is requiredXx_NEWLINE_xXOther investigational agent within 3 weeks prior to initiation of study therapyXx_NEWLINE_xXNo investigational agent within 21 days prior to registrationXx_NEWLINE_xXPatients who are receiving any other investigational agents, or have received an investigational agent within the past 30 daysXx_NEWLINE_xXPatient is receiving another investigational agent for the treatment of cancerXx_NEWLINE_xXPatients who have previously received temsirolimus, another mTOR inhibitor, or any other investigational agentXx_NEWLINE_xXPatients who are receiving any other investigational agents, or have received an investigational agent within the past 30 daysXx_NEWLINE_xXPatients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within five half-lives of the compound or 3 months, whichever is greaterXx_NEWLINE_xXPatients who are receiving any other investigational agentXx_NEWLINE_xX